Can-Fite BioPharma Reports Positive Clinical Data in Pancreatic Cancer and Liver Cancer, Expands IP Portfolio and Advances Metabolic Disease Pipeline.

Thursday, Mar 26, 2026 9:28 am ET1min read
CANF--

Can-Fite BioPharma reported 2025 financial results and clinical progress, highlighting positive data in Phase 2a pancreatic cancer and 9 years of cancer-free survival in a liver cancer patient. The company also observed complete resolution of esophageal varices in a patient with decompensated cirrhosis and expanded Namodenoson's therapeutic potential into metabolic diseases. Can-Fite strengthened its intellectual property portfolio with multiple patent allowances across key territories.

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet